Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease

Neurology

Volumn 65, Issue 6, 2005, Pages 941-943

  Van Oostrom, J C H ^a   Maguire, R P ^a   Verschuuren Bemelmans, C C ^a   Veenma Van Der Duin, L ^a   Pruim, J ^a   Roos, R A C ^b   Leenders, K L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE; GLUCOSE; RACLOPRIDE;

ADULT; ARTICLE; BRAIN METABOLISM; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GLUCOSE METABOLISM; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MALE; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; TRINUCLEOTIDE REPEAT;

EID: 25444467559     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000176071.08694.cc     Document Type: Article

References (10)

1. Gomez-Tortosa E, MacDonald ME, Friend JC, et al. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol 2001;49:29-34.
2. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119:2085-2095.
3. Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 1998;282:1072-1074.
4. Paulsen JS, Zhao H, Stout JC, et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 2001;57:658-662.
5. Penney JB, Jr., Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
6. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72.
7. Volkow ND, Logan J, Fowler JS, et al. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry 2000;157:75-80.
8. Pavese N, Andrews TC, Brooks DJ, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003;126:1127-1135.
9. Augood SJ, Faull RL, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 1997;42:215-221.
10. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000;101:57-66.